Cargando…

A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients

OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaohui, Yang, Yan, Gong, Daokai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Riyadh : Armed Forces Hospital 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726829/
https://www.ncbi.nlm.nih.gov/pubmed/28416790
http://dx.doi.org/10.17712/nsj.2017.2.20160557
_version_ 1783285765070913536
author Hu, Xiaohui
Yang, Yan
Gong, Daokai
author_facet Hu, Xiaohui
Yang, Yan
Gong, Daokai
author_sort Hu, Xiaohui
collection PubMed
description OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed to search “PubMed”, “Springer” and “Medline” databases until July 2016 and standard mean difference (Std.MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources. RESULTS: Seven studies involved 1151 participants were pooled. The CSF VLP-1 in AD patients was higher than that in healthy controls and MCI patients (pooled Std.MD=0.81, 95% CI: [0.47, 1.16], p<0.00001). As shown by subgroup analysis, population variations were one of heterogeneity sources. Meta-regression revealed that Hedges’s g of CSF VLP-1 was correlated with Std.MD of t-tau (r=0.560, p=0.006) and Ab42 (r=-0.386, p=0.013). CONCLUSION: The CSF VLP-1 in AD patients is higher than that in healthy controls and MCI patients. The changes of VLP-1 in AD patients relative to healthy controls and MCI patients is less pronounced than that of core biomarkers, such as Ab42, t-tau and p-tau. Population variations, increasing t-tau and decreasing Ab42 in AD patients relative to healthy controls and MCI patients were the main sources of heterogeneity.
format Online
Article
Text
id pubmed-5726829
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Riyadh : Armed Forces Hospital
record_format MEDLINE/PubMed
spelling pubmed-57268292017-12-18 A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients Hu, Xiaohui Yang, Yan Gong, Daokai Neurosciences (Riyadh) Systematic Review OBJECTIVE: To compare cerebrospinal fluid visinin-like protein-1 (CSF VLP-1) in alzheimer’s disease (AD) with that in healthy controls and mild cognitive impairment (MCI) patients and find out possible sources of heterogeneity. METHOD: “Visinin-like protein-1” and “alzheimer’s disease” were employed to search “PubMed”, “Springer” and “Medline” databases until July 2016 and standard mean difference (Std.MD) was calculated. Besides, subgroup analysis and meta-regression were performed to explore the possible heterogeneity sources. RESULTS: Seven studies involved 1151 participants were pooled. The CSF VLP-1 in AD patients was higher than that in healthy controls and MCI patients (pooled Std.MD=0.81, 95% CI: [0.47, 1.16], p<0.00001). As shown by subgroup analysis, population variations were one of heterogeneity sources. Meta-regression revealed that Hedges’s g of CSF VLP-1 was correlated with Std.MD of t-tau (r=0.560, p=0.006) and Ab42 (r=-0.386, p=0.013). CONCLUSION: The CSF VLP-1 in AD patients is higher than that in healthy controls and MCI patients. The changes of VLP-1 in AD patients relative to healthy controls and MCI patients is less pronounced than that of core biomarkers, such as Ab42, t-tau and p-tau. Population variations, increasing t-tau and decreasing Ab42 in AD patients relative to healthy controls and MCI patients were the main sources of heterogeneity. Riyadh : Armed Forces Hospital 2017-04 /pmc/articles/PMC5726829/ /pubmed/28416790 http://dx.doi.org/10.17712/nsj.2017.2.20160557 Text en Copyright: © Neurosciences http://creativecommons.org/licenses/by/3.0/ Neurosciences is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.
spellingShingle Systematic Review
Hu, Xiaohui
Yang, Yan
Gong, Daokai
A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title_full A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title_fullStr A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title_full_unstemmed A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title_short A meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
title_sort meta-analysis of cerebrospinal fluid visinin-like protein-1 in alzheimer’s disease patients relative to healthy controls and mild cognitive impairment patients
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726829/
https://www.ncbi.nlm.nih.gov/pubmed/28416790
http://dx.doi.org/10.17712/nsj.2017.2.20160557
work_keys_str_mv AT huxiaohui ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients
AT yangyan ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients
AT gongdaokai ametaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients
AT huxiaohui metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients
AT yangyan metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients
AT gongdaokai metaanalysisofcerebrospinalfluidvisininlikeprotein1inalzheimersdiseasepatientsrelativetohealthycontrolsandmildcognitiveimpairmentpatients